Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia
KC Maki, JR Guyton, CE Orringer… - Journal of clinical …, 2016 - Elsevier
Background Cardiovascular outcomes trials of fibrates, niacin, or omega-3 fatty acids alone,
or added to a statin, have not consistently demonstrated reduced risk, but larger, statistically
significant clinical benefits have been reported in subgroups with elevated triglycerides (TG)
and/or elevated TG plus low high-density lipoprotein cholesterol (HDL-C). Objective To
perform a meta-analysis of the effects of therapies targeting TG and TG-rich lipoprotein
cholesterol on cardiovascular disease event risk in subjects with elevated TG or elevated TG …
or added to a statin, have not consistently demonstrated reduced risk, but larger, statistically
significant clinical benefits have been reported in subgroups with elevated triglycerides (TG)
and/or elevated TG plus low high-density lipoprotein cholesterol (HDL-C). Objective To
perform a meta-analysis of the effects of therapies targeting TG and TG-rich lipoprotein
cholesterol on cardiovascular disease event risk in subjects with elevated TG or elevated TG …